Other Events. A copy of the press release announcing the Registered Offering and the Concurrent Private Placement is attached to this Current Report as Exhibit 99.1.

Entry into a Material Definitive Agreement. Purchase Agreements On August 13, 2026, Dyadic International, Inc. (the “Company”) entered into (i) a common stock purchase agreement (the “Common Stock Purchase Agreement”) with certain investors (the “Common Stock Purchasers”), pursuant to which the Company agreed to issue and sell to such Common Stock Purchasers in a registered direct offering (the “Registered Offering”) an aggregate of 3,625,000 shares (the “Shares”) of common stock, par value $…

Unregistered Sales of Equity Securities. The information set forth in

Results of Operations and Financial Condition. On August 12, 2026, Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. (a) On June 18, 2026, Dyadic International, Inc. (the “Company” or “Dyadic”) received a notification (the “Notification”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq has initiated a process that could result in the delisting of the Company’s securities from Nasdaq due to the Company’s failure to comply with Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”)…

Regulation FD Disclosure. On May 28, 2026, Dyadic International, Inc. (the “Company” or “Dyadic”) issued a press release titled “Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development: Collaboration Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadic’s C1 Platform Capabilities for Fast, Scalable Biologic Production”. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by refe…

Results of Operations and Financial Condition. On May 13, 2026, Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. (a) On March 27, 2026, Dyadic International, Inc. (the “Company” or “Dyadic”) received a deficiency notice (the “Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is out of compliance with the technical minimum requirements for continued listing under Nasdaq Listing Rule 5550(b) (the “Continued Listing Re…

Results of Operations and Financial Condition. On March 25, 2026, Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18…

Entry into a Material Definitive Agreement. On March 6, 2026, Dyadic International, Inc. (the “Company”) entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Craig-Hallum Capital Group LLC, as sales agent (the “Sales Agent”), pursuant to which the Company may offer and sell from time to time, at its option, shares of the Company’s common stock having an aggregate offering price of up to $4,237,818 from time to time through the Sales Agent. The issuance and sale,…

Entry into a Material Definitive Agreement. On December 23, 2025, Dyadic International, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Form of Senior Secured Convertible Promissory Note due March 8, 2027 (the “Convertible Notes”). Pursuant to the Amendment, (i) the Maturity Date (as defined in the Convertible Notes) shall be extended from March 8, 2027 to December 31, 2027, (ii) the conversion price upon which the Convertible Notes will be convertible into shares of t…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. (a) On December 19, 2025, Dyadic International, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the Company’s securities have not maintained the minimum bid price of at least $1 per share required by the conti…

Results of Operations and Financial Condition. On November 12, 2025, Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Sect…

Entry into a Material Definitive Agreement. On September 15, 2025, Dyadic International, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Security Agreement, dated March 8, 2024 (the “Security Agreement”), with a majority of the current holders of the Company’s Senior Secured Convertible Promissory Notes due March 8, 2027. Pursuant to the Amendment, Schedule A of the Security Agreement was replaced in its entirety to reflect updates to the Secured Parties (as defined in…

Results of Operations and Financial Condition. On August 13, 2025, Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18…

Entry into a Material Definitive Agreement. On July 30, 2025, Dyadic International, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Craig-Hallum Capital Group LLC, in its capacity as underwriter (the “Underwriter”), relating to the issuance and sale (the “Offering”) of 6,052,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”). The public offering price in the Offering is $0.95 per share of Common Stock. The net…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. (a) On July 17, 2025, Dyadic International, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the Company’s securities have not maintained the minimum bid price of at least $1 per share required by the continued…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. (a) On June 23, 2025, Dyadic International, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the Company’s securities have not maintained the minimum Market Value of Listed Securities (“MVLS”) of $35 million re…

President — Joseph Hazelton: Joseph Hazelton was promoted to President while continuing as Chief Operating Officer.

Results of Operations and Financial Condition On May 14, 2025, Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the quarter ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of…

Entry into a Material Definitive Agreement. On May 1, 2025, Dyadic International, Inc. (the “Company”) entered into a second amendment (the “Second Amendment”) to the Form of Senior Secured Convertible Promissory Note due March 8, 2027 (the “Convertible Notes”) with a majority of the current holders of the Convertible Notes. Pursuant to the Second Amendment, the Redemption Date (as defined in the Second Amendment) now will fall on December 1, 2026. The foregoing description of the Second Amen…

Director — Arindam Bose: Mr. Bose is retiring as a director of the Board, effective at the Company’s annual meeting.

The information in this Item 2.02, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. Such information shall not be incorporated by reference in any filing under the Securities Act of 1933 (the “Securities Act”), as amended, or the Exchange Act, except as shall be expressly set forth by speci…

Entry into a Material Definitive Agreement. On November 16, 2024, Dyadic International, Inc. (the “Company”) entered into an agreement (the “Agreement”) with the Bill & Melinda Gates Foundation (the “Gates Foundation”) relating to a grant in the amount of $3,092,136.00 awarded from the Gates Foundation for the cell line development of monoclonal antibodies targeting respiratory syncytial virus and malaria utilizing the Company’s proprietary C1 protein production platform to provide globally a…

Results of Operations and Financial Condition On November 12, 2024, Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the quarter ended September 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Secti…